retatrutide phase 2 trial obesity nejm 2023 Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks Triple hormone receptor agonist retatrutide
Description
The dominant driver is reduced caloric intake
The FDA does not approve nor review compounded products for safety, effectiveness, or quality
Recommendations for evaluation of bladder and bowel function in pre-clinical spinal cord injury research
Ready to Start a Medically Supervised Program
Contact NHS 111 for urgent advice or attend an urgent treatment centre or A&E if severely unwell
